Table 4.

HLTF expression in cervix, head and neck and thyroid cancers

Group	Ethnicity	Assay	Normal (20)	CIN I (32)	CIN II–III (35)	SCC (10)	ADC (12)	AIS (10)
HLTF expression in cervix cancer ( n )
Capouillez et al [15]	Europe	IHC	±	+	++	+++	+++	+++
		WB	Wt form	/	Wt form	Truncated forms	/	/

Group	Ethnicity	Assay	Disease-free (16)			Recurrence (11)
HLTF expression in cervix cancer after curative radiotherapy ( n )
Cho et al. [86]	Asia	IHC	+	++	+++	+	++	+++
			2	10	4	0	2	9

Group	Ethnicity	Assay	HSCC
			Tumor-free (27)	Dyspl. (48)		HSCC IV (100)
HLTF expression in head and neck cancer ( n ): Hypopharyngeal Squamous Cell Carcinoma (HSCC) and Laryngeal Squamous Cell Carcinoma (LSCC)
Capouillez et al. [10, 14]	Europe	IHC	+	++		+++
			Nucleocytopl.	Nucleocytopl.		Cytopl. shift
		WB	Truncated form (2)	/		Wt + truncated forms (3)
		Assay	LSCC
			Tumor-free (33)	Dyspl. (44)	LSCC I-II (40)	LSCC IV (16)
		IHC	+++	++	++	++
			Cytopl.	Nucleocytopl.	Nucleocytopl.	Nucleocytopl.
		WB	/	/	Wt + truncated forms (3)

Group	Ethnicity	Assay	Cohort I (80)
			Adenoma (20)	Papillary carcinoma (40)	Follicular carcinoma (12)	Anaplastic carcinoma (8)
HLTF expression in thyroid cancer ( n )
Arcolia et al. [88]	Europe	IHC	+++	++	±	±
			Nucleus	Cytopl.	Nucleocytopl.	Nucleocytopl.
			Cohort II (69)
			Benign lesions (40)		Malignant lesions (29)
			+++		+ to ±
			Nucleus		Nucleocytopl.

The number of patients is indicated under the brackets. CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; ADC, adenocarcinoma; AIS, adenocarcinoma in situ; IHC, immunohistochemistry; WB, western blotting; Wt, wild-type; for the staining intensity: ±, weak; +, low; ++, moderate; +++, high